Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

NCT01280929 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
54
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

José Cunha-Vaz